Search hospitals > Nevada > Las Vegas

OptumCare Cancer Care at Fort Apache

Claim this profile
Las Vegas, Nevada 89148
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Adenocarcinoma
217 reported clinical trials
2 medical researchers
Photo of OptumCare Cancer Care at Fort Apache in Las VegasPhoto of OptumCare Cancer Care at Fort Apache in Las VegasPhoto of OptumCare Cancer Care at Fort Apache in Las Vegas

Summary

OptumCare Cancer Care at Fort Apache is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. OptumCare Cancer Care at Fort Apache is involved with conducting 217 clinical trials across 365 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.

Area of expertise

1Cancer
Global Leader
OptumCare Cancer Care at Fort Apache has run 97 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Lung Cancer
Global Leader
OptumCare Cancer Care at Fort Apache has run 38 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at OptumCare Cancer Care at Fort Apache

Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Prostate Cancer
Tumors
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at OptumCare Cancer Care at Fort Apache?
OptumCare Cancer Care at Fort Apache is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Tumors, Adenocarcinoma and other specialties. OptumCare Cancer Care at Fort Apache is involved with conducting 217 clinical trials across 365 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.